The range is part of PGT Healthcare, a joint venture between the Procter & Gamble Company and Teva Pharmaceutical Industries Ltd.
The partnership follows the sale of Melbourne-based Swisse to Hong Kong baby formula manufacturer, Biostime, for $1.67 billion in September. At the time of the acquisition the vitamin maker said it was planning to turn its focus to international expansion.
Biostime secured a 83 per cent interest in the Australian vitamins giant, with Biostime one of the leading premium infant formula, baby food, and baby care producers in Asia with revenues of A$934 million in FY14. Its brands include Biostime, Adimil, BMcare, and Mama100.
Swisse’s range consists of 29 supplements developed specially for men, women, and children. The Procter & Gamble Company and Teva Pharmaceutical Industries Ltd formed the PGT Healthcare LLP joint venture inNovember 2011. PGT Healthcare manufactures and markets more than 200 consumer healthcare brands in more than 70 countries around the world.